CD80 and breast cancer: The safety of an allogeneic vaccine was investigated in a clinical trial sponsored by Paul Ehrlich Institute, Langen, Germany (NCT01127074, Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422) (KS2422-vacc)) and in another clinical trial sponsored by Beth Israel Deaconess Medical Center (NCY00625755, A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogenic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusion in Patients With AJCC Stage IV Renal Cell Carcinoma) [95].